TITLE

Effectiveness of Biofield Therapy for Individuals With Sickle Cell Disease in Africa

AUTHOR(S)
Tite Mikobi Minga; Fridolin Kodondi Kule Koto; Hillaire Egboki; Kiyoshi Suzuki
PUB. DATE
January 2014
SOURCE
Alternative Therapies in Health & Medicine;Jan/Feb2014, Vol. 20 Issue 1, p20
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Context * Individuals with sickle cell disease (SCD) in Africa have to manage most of their painful episodes at home, mainly due to insufficient medical services. In the past, the research team had observed that some individuals with SCD had experienced symptomatic improvement after administration of biofield therapy. Objective * The research team intended to evaluate the influence of repeated administration of biofield therapy on clinical outcomes for individuals with SCD in Africa. Design * The research team designed a prospective, open-label, nonrandomized, case-control study. Setting * This study was performed at Le Centre de Médecine Mixte d'Anémie SS (CMMASS) in Kinshasa, Democratic Republic of Congo (DRC). Participants * Participants were individuals with SCD who received treatments at CMMASS. Intervention * Twenty participants aged 3-36 y underwent Okada purifying therapy (OPT), a form of biofield therapy, every weekday for 1 y (OPT group). OPT was administered by certified practitioners approved by the MOA International Corporation. The research team also constructed an age- and gender-matched control group (n = 20) from regular patients at the clinic. Outcome Measures * Participants in both groups received blood tests at baseline, after 6 mo, and at end of the 1-y intervention period. A follow-up survey was also conducted 33 mo after the 1-y administration of OPT. Results * The OPT group showed a significant improvement in its blood data, including hemoglobin, total bilirubin, alanine aminotransferase (ALT), creatinine, and white blood cell (WBC) count (P<.001). The control group had less improvement in hemoglobin (P<.001) and total bilirubin (P<.001) than the OPT group. Its creatinine level increased significantly (P<.001), and ALT and WBC count remained at the same level after 1 y. For the OPT group, SCD-related episodes, such as painful crises, blood transfusions, and hospitalizations, decreased more significantly than for the control group (P < .001). The follow-up survey revealed that those who continued using OPT regularly had remained in better condition for approximately 3 y after the intervention period than those who did not (P = .0014). Conclusion * Repeated administration of biofield therapy is considered effective for individuals with SCD who have various symptoms, although the care given by the practitioners may have had some influence on the clinical outcomes.
ACCESSION #
93819192

 

Related Articles

  • Hypertransfusion Therapy in Sickle Cell Disease in Nigeria. Adewoyin, Ademola Samson; Obieche, Jude Chike // Advances in Hematology;2014, p1 

    Introduction. Hypertransfusion refers to chronic blood transfusion therapy aimed at ameliorating disease complications in various haemopathies particularly the haemoglobinopathies. In sickle cell disease, hypertransfusion is aimed at maintaining patient's haemoglobin level at 10 to 11 g/dL using...

  • Fetal fix.  // New Scientist;6/3/95, Vol. 146 Issue 1980, p11 

    Reports on the discovery of a drug called hydroxyurea that reduces the number of sickle cells in patients with sickle cell anemia. Production of defective form of hemoglobin; Treatments for the condition; Side effects of drug; Researchers' claim that drug interferes with the working of DNA.

  • Youthful cure for sickle cell disease.  // New Scientist;10/22/2011, Vol. 212 Issue 2835, p19 

    The article explores a report published in "Science" by medical researcher Stuart Orkin and team that an experimental blockade of the BCL11A gene that regulates the change from fetal to adult haemoglobin production in the body cured mice of a sickle cell anaemia-like condition.

  • Does blood transfusion affect pituitary gonadal axis and sperm parameters in young males with sickle cell disease? Soliman, Ashraf T.; Yasin, Mohamed; El-Awwa, Ahmed; Abdelrahman, Mohamed O.; De Sanctis, Vincenzo // Indian Journal of Endocrinology & Metabolism;Nov/Dec2013, Vol. 17 Issue 6, p962 

    Objective: We evaluated the effect of packed red cell transfusion (PCTx) on serum concentrations of gonadotropins luteinizing hormone and follicle-stimulating hormone (LH and FSH) and testosterone (T) levels and measured sperm parameters in young adults with sickle cell disease (SCD) on top-up...

  • How One Mother Helps Her Son Cope With Sickle Cell Disease. Slagle, Dana // Jet;9/17/2007, Vol. 112 Issue 11, p24 

    The article describes the experience of mother Deborah Clark, whose son Benjamin has sickle cell anemia. The disease is hereditary, and there is no cure. A method of treatment is penicillin administration for children. Blood transfusions are also common treatment. Clark received blood...

  • Transfusion-independent β0-thalassemia after bone marrow transplantation failure: proposed involvement of high parental HbF and an epigenetic mechanism. Paciaroni, Katia; Lucarelli, Guido; Martelli, Fabrizio; Migliaccio, Anna Rita; von Lindern, Marieke; Borg, Joseph; Gillemans, Nynke; van Dijk, Thamar B.; Philipsen, Sjaak // American Journal of Blood Research;2014, Vol. 4 Issue 1, p27 

    Currently, bone marrow transplantation is the only curative treatment for β-thalassemia and sickle cell disease. In rare cases, sustained and full fetal hemoglobin production was observed in patients after failure of bone marrow transplantation. This rendered the patients transfusion-free,...

  • Acute Hemolysis in a Patient with Anti-U Despite a Negative MMA Test. LaFrance, Delecia R.; Hawthorne, Linda; Menchu Ong; Veillon, Diana; Cotelingam, James // Laboratory Medicine;Nov2010, Vol. 41 Issue 11, p659 

    Obtaining compatible units for patients with alloantibodies to high frequency antigens poses an extreme challenge for transfusion specialists because these rare units are expensive, in high demand, and are often needed emergently. However, because not all antibodies are clinically significant,...

  • Management of Sickle Cell Disease: A Review for Physician Education in Nigeria (Sub-Saharan Africa). Adewoyin, Ademola Samson // Anemia (20901267);1/18/2015, Vol. 2015, p1 

    Sickle cell disease (SCD) predominates in sub-Saharan Africa, East Mediterranean areas, Middle East, and India. Nigeria, being the most populous black nation in the world, bears its greatest burden in sub-Saharan Africa. The last few decades have witnessed remarkable scientific progress in the...

  • Acute splenic sequestration crisis in an adult with sickle cell anaemia. Tavare, Aniket N.; Wrench, David; Cooper, Nichola // British Journal of Hospital Medicine (17508460);Mar2012, Vol. 73 Issue 3, p168 

    The article presents a case study of a 25-year-old Caribbean woman with sickle cell anaemia (HbSS) who presented again with lower back and limb pain, after she had been diagnosed with vaso-occlusive crisis and treated with opiate analgesia. Acute splenic sequestration crisis was detected, and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics